CLSN Celsion Corporation

0.29
+0  (6%)
Previous Close 0.28
Open 0.29
Price To book 1.29
Market Cap 16.31M
Shares 55,466,000
Volume 963,159
Short Ratio 0.65
Av. Daily Volume 2,768,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Failed to meet primary endpoint. New Phase 3 trial initiated, with enrollment to be completed early 2018 with first interim efficacy endpoint due 4Q 2018.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1b interim data released January 17, 2016 with final data due 2Q 2017.
GEN-1 OVATION
Ovarian cancer